Results 1 to 10 of about 10,553 (193)
Journal of Pharmacological Sciences, 2022 Podocyte injury is responsible for nephrotic syndrome. Previously, we found that tadalafil, a phosphodiesterase 5 inhibitor, might have protective effects on podocytes.
Natsumi Tomita +7 more
doaj +2 more sources
Maternal Blood Concentration of Tadalafil and Uterine Blood Flow in Pregnancy
Medicina, 2019 Background and Objectives: Tadalafil for treatment of fetal growth restriction (FGR) or preeclampsia is given once a day orally. The drug kinetics of tadalafil were investigated to determine the ideal dosage to promote uterine blood flow.
Hiroaki Tanaka +7 more
doaj +2 more sources
Effect of Ticagrelor, a Cytochrome P450 3A4 Inhibitor, on the Pharmacokinetics of Tadalafil in Rats
Pharmaceutics, 2019 Tadalafil is a cytochrome P450 (CYP) 3A4 substrate. Because there are few data on drug-drug interactions, it is advisable to take sufficient consideration when co-administering tadalafil with CYP3A4 inducers or inhibitors.
Young-Guk Na +6 more
doaj +2 more sources
Portopulmonary hypertension practice patterns after liver transplantation
Liver Transplantation, EarlyView., 2022 Abstract Portopulmonary hypertension (POPH) is a type of pulmonary arterial hypertension occurring exclusively in those with portal hypertensive liver disease. Liver transplantation (LT) can significantly improve outcomes. Current guidelines counsel against immediate adjustments to targeted therapy after LT and suggest routine echocardiography as ...
Arun Jose +3 more
wiley +1 more source
A comparative Study of Tadalafil versus Tadalafil combined with Alpha Lipoic Acid in the treatment of Erectile Dysfunction in Diabetic Patients [PDF]
Al-Azhar International Medical Journal, 2022 Background: Erectile dysfunction (ED) is a worldwide health issue that has an influence on men's and their spouses' quality of life. The etiology of ED may be organic, psychogenic or mixed.
Hassan Abdel-Wahab +2 more
doaj +1 more source
BMJ Open Diabetes Research & Care, 2020 Introduction Sexual dysfunction is a common complication in men with type 2 diabetes and is often refractory to treatment. This study investigated the long-term influence of the phosphodiesterase 5 inhibitor (PDE5I) tadalafil on the level of sex hormones
Akiko Itoga +5 more
doaj +1 more source
BMC Urology, 2019 Background Chronic inflammation is thought to be a major causative factor for the development of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). Tadalafil, a phosphodiesterase type 5 inhibitor (PDE5-I), which has been used for
Mikio Sugimoto +11 more
doaj +1 more source
Jurnal Urologi Indonesia, 2017 Purpose: Assess the efficacy of combined α1-adrenergic blocker (tamsulosin 0,4 mg) and PDE5 inhibitor (tadalafil 5 mg) therapy compared to tadalafil or tamsulosin alone in treating patient BPH with LUTS and ED.
Muhammad Ridha +2 more
doaj +1 more source
Asian Journal of Andrology, 2015 The study was to compare treatment preference, efficacy, and tolerability of sildenafil citrate (sildenafil) and tadalafil for treating erectile dysfunction (ED) in Chinese men naοve to phosphodiesterase 5 (PDE5) inhibitor therapies.
Wen-Jun Bai +9 more
doaj +1 more source
Physiological Reports, 2021 Preclinical diastolic dysfunction (PDD) results in impaired cardiorenal response to volume load (VL) which may contribute to the progression to clinical heart failure with preserved ejection fraction (HFpEF).
Siu‐Hin Wan +5 more
doaj +1 more source